Noninvasive in vivo imaging of diabetes-induced renal oxidative stress and response to therapy using hyperpolarized 13C dehydroascorbate magnetic resonance. by Keshari, Kayvan R et al.
UCSF
UC San Francisco Previously Published Works
Title
Noninvasive in vivo imaging of diabetes-induced renal oxidative stress and response to 


















eScholarship.org Powered by the California Digital Library
University of California
Kayvan R. Keshari,1,2 David M. Wilson,3 Victor Sai,3 Robert Bok,3 Kuang-Yu Jen,3 Peder Larson,3
Mark Van Criekinge,3 John Kurhanewicz,3 and Zhen J. Wang3
Noninvasive In Vivo Imaging of
Diabetes-Induced Renal




Diabetes 2015;64:344–352 | DOI: 10.2337/db13-1829
Oxidative stress has been proposed to be a unifying
cause for diabetic nephropathy and a target for novel
therapies. Here we apply a new endogenous reduction-
oxidation (redox) sensor, hyperpolarized (HP) 13C
dehydroascorbate (DHA), in conjunction with MRI to
noninvasively interrogate the renal redox capacity in
a mouse diabetes model. The diabetic mice demonstrate
an early decrease in renal redox capacity, as shown by
the lower in vivo HP 13C DHA reduction to the antioxidant
vitamin C (VitC), prior to histological evidence of nephrop-
athy. This correlates with lower tissue reduced glutathi-
one (GSH) concentration and higher NADPH oxidase 4
(Nox4) expression, consistent with increased superoxide
generation and oxidative stress. ACE inhibition restores
the HP 13C DHA reduction to VitC with concomitant nor-
malization of GSH concentration and Nox4 expression in
diabetic mice. HP 13C DHA enables rapid in vivo assess-
ment of altered redox capacity in diabetic renal injury and
after successful treatment.
Diabetes (type 1 and type 2) currently affects 8.3% of the
population in the U.S. (1). Diabetic nephropathy develops
in about one-third of diabetic patients and is one of the
most devastating complications from diabetes (2). In di-
abetes, chronic hyperglycemia leads to excessive production
of reactive oxygen species (ROS), exceeding local antioxi-
dant capacity and leading to oxidative stress. Oxidative
stress has been proposed to be a unifying cause for the
onset and progression of diabetic nephropathy, and a tar-
get for novel therapies (3–7).
The link among diabetes, oxidative stress, and renal
injury has been illustrated in many studies. A primary
source of ROS and oxidative stress in renal cells is
NAPDH oxidase 4 (Nox4; EC 1.6.3.1), which is activated
by chronic hyperglycemia (8–13). Nox4 belongs to a family
of enzymes responsible for the production of ROS (super-
oxide) by transferring electrons across the membrane
from NADPH to molecular oxygen. Other isoforms of
the Nox family expressed in the kidneys include Nox1
and Nox2, but these are much less abundant in compar-
ison with Nox4. Nox4-dependent superoxide generation
and oxidative stress have been shown to mediate glomer-
ular hypertrophy and mesangial matrix accumulation
(8,14), which are key histological features of diabetic
nephropathy. Nox4-induced oxidative stress also contributes
to tubulointerstitial fibrosis seen in diabetic nephropathy
(15,16). ACE inhibitors and angiotensin receptor blockers,
commonly used classes of drugs used to treat diabetic kidney
disease, are thought to protect the kidneys in part by sup-
pressing Nox4-mediated superoxide generation (17,18).
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Given the major role of oxidative stress in diabetes, a non-
invasive strategy to interrogate oxidative stress in vivo may
further enhance our understanding of diabetic renal injury.
Such a strategy may also improve the monitoring of the
onset and progression of diabetic nephropathy and, impor-
tantly, provide biomarkers for response to new therapies.
Hyperpolarized (HP) 13C magnetic resonance (MR) spec-
troscopy is a new molecular imaging technique that allows
noninvasive investigation of dynamic metabolic and phys-
iological processes in real time (19). Hyperpolarization,
achieved through the dynamic nuclear polarization tech-
nique (20), can provide dramatic enhancement of the
13C nuclear MR signals (.50,000-fold at 3 T) of the sub-
strates as well as subsequent metabolic products. Recently,
we developed HP 13C dehydroascorbate (DHA) as an en-
dogenous reduction-oxidation (redox) sensor (21). DHA is
an oxidized form of vitamin C (VitC); it is rapidly taken up
by cells via the GLUT1, GLUT3, and GLUT4 transporters
(22) and is reduced to VitC via a glutathione-dependent
mechanism, with coupled reactions with NADPH (Fig. 1).
Glutathione, which usually exists in its reduced form
(GSH), functions as a key antioxidant by scavenging ROS.
It follows that the rate of DHA reduction to VitC reflects
cellular redox capacity (23), and serves as an indicator for
oxidative stress. We have previously observed rapid in vivo
conversion of HP 13C DHA to 13C VitC in tissues expected
to be rich in GSH, such as in the kidneys, liver, and brain,
and in prostate cancer in a TRAMP (transgenic adenocar-
cinoma of the mouse prostate) model (21,24).
In this study, we apply HP 13C DHA to interrogate the
renal redox capacity in a mouse model of type 2 diabetes
and diabetic nephropathy. We show lower HP 13C DHA
reduction to 13C VitC during the development of diabetic
kidney injury, and its normalization after treatment with
an ACE inhibitor (ramipril). HP 13C DHA reduction to
VitC reflects the intracellular GSH concentrations and
provides a noninvasive probe for monitoring redox alter-
ations in vivo.
RESEARCH DESIGN AND METHODS
Animals
All procedures were approved by the Institutional Animal
Care and Use Committee. Male mice homozygous for the
leptin receptor mutation (BKS.Cg-leprdb/leprdb [db/db mice])
and their age-matched control littermates (BKS.Cg-leprdb/+
[db/m mice]) were purchased from The Jackson Laboratory
(Bar Harbor, ME). The db/db mice are one of the most
commonly used murine models of human type 2 diabetes
and diabetic nephropathy. The animals were allowed free
access to standard chow and drinking water ad libitum.
The db/db mice at 8, 12, and 16 weeks of age (n = 5 for
each age group), and their age-matched db/m mice (n = 4
for each age group) underwent MRI studies, and subse-
quent histological and biochemical assays described be-
low. In addition, a separate group of db/db mice (n = 5)
were treated with an ACE inhibitor, ramipril (Sigma-
Aldrich; 10 mg/kg daily via drinking water) from 8 to
12 weeks of age, followed by MRI and tissue analysis.
Contemporaneous 24-h urine samples were collected
from the mice for determination of urine albumin excre-
tion by ELISA (Albuwell; Exocell, Philadelphia, PA). Urine
8-hydroxy-29-deoxyguanosine (8-OHdG) concentrations
were measured using a competitive ELISA kit (OxiSelect
Oxidative DNA Damage ELISA Kit; Cell Biolabs, San Diego,
CA) as previously described (14). Urinary 8-OHdG excretion
was expressed as a total amount in nanograms over 24 h.
Fasting blood glucose levels of the mice were also measured
at the time of the MRI (AlphaTRAK; Abbott Laboratories).
HP 13C MRI Studies
The db/db mice and their control littermates db/m mice
were fasted for 6 h prior to image acquisition. A tail vein
catheter was placed for intravascular access. A 2.2 mol/L
solution of [1-13C]DHA in dimethyacetamide containing
15 mmol/L OX063 trityl radical (Oxford Instruments) was
HP on a HyperSense dynamic nuclear polarization in-
strument (Oxford Instruments). The frozen sample was
Figure 1—Schematic representation of HP DHA uptake and its subsequent reduction to VitC. The green box indicates GLUT1. DHA is
reduced to VitC by DHA reductase (EC 1.8.5.1) in a glutathione-dependent mechanism via coupled reaction to NADPH.
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dissolved in distilled water containing 0.3 mmol/L EDTA.
Imaging was performed using a 3-T MRI scanner (GE
Healthcare, Waukesha, WI) equipped with a multinuclear
spectroscopy hardware package. The radiofrequency coil
used in these experiments was a dual-tuned 1H-13C coil
with a quadrature 13C and 1H channels. Prior to 13C stud-
ies, three-plane T2-weighted images were acquired for an-
atomic localization (echo time 100 ms; repetition time
4 s; six averages) using a standard fast spin echo sequence.
13C MR spectroscopic imaging studies were then acquired
25 s postinjection of 15 mmol/L HP 13C DHA, at 5-mm
isotropic resolution, as previously published (21,24).
Histological Evaluation
Two-micrometer-thick renal sections were cut from 10%
formalin-fixed, paraffin-embedded kidney samples, and
stained with periodic acid Schiff (PAS). Each section was
scanned at high magnification (3400) to produce digi-
tized whole slide images and was loaded into the ImageJ
software (National Institutes of Health). Ten randomly
selected glomeruli in the outer cortex were selected. The
percent glomerular mesangial area was calculated as the
fraction of the total glomerular tuft cross-sectional area,
as previously described (25). 8-OHdG immunostaining of
the renal slices was performed using anti–8-OHdG mouse
monoclonal antibody (Santa Cruz Biotechnology). In brief,
ethanol-fixed sections were prepared, and antigen re-
trieval was performed using a microwave. Antibodies
against 8-OHdG were used for the primary reactions fol-
lowed by secondary reactions with biotin-labeled anti-
mouse goat IgG.
Glutathione Measurements
Renal tissues were homogenized in PBS with EDTA.
Protein was precipitated with 10% metaphosphoric acid,
and glutathione concentrations were assayed spectropho-
tometrically using a commercially available 5,59-dithio-bis-
2-(nitrobenzoic acid)–based absorbance assay (Cayman
Chemical).
Real-Time PCR
Total RNA was isolated from renal tissues from db/db
(n = 4) and db/m (n = 4) mice using the Qiagen RNeasy
Kit, and was reverse transcribed using SuperScript III
Reverse Transcriptase (Invitrogen) according to the man-
ufacturer’s instructions. Mouse Nox1, Nox2, and Nox4
Invitrogen primers were obtained from Life Technologies,
and real-time PCR determination of cDNA amounts was
performed. Relative expression to control gene hypoxan-
thine phosphoribosyltranserase (HPRT) was determined
using the DCt method.
Statistical Analysis
Student t tests and one-way ANOVA with Tukey-Kramer
post hoc tests were used to assess the difference between
relevant groups using the statistical software package STATA
version 8.0. All values are reported as the mean 6 SE.
A P value of ,0.05 was considered statistically significant.
RESULTS
db/dbMice Have Lower HP 13C DHA Reduction to VitC
We performed HP 13C DHA MR spectroscopic imaging in
db/db mice and age-matched db/m mice at 8, 12, and 16
weeks. The db/db mice have been reported to reliably de-
velop frank hyperglycemia by 8 weeks of age (26). Table 1
summarizes the weight, blood glucose level, and urine
albumin excretion in the db/db and db/m mice in this
study. Figure 2A shows representative MR spectra for
voxels corresponding to kidneys in a db/m and a db/db
mouse at 12 weeks of age after the injection of HP 13C
DHA, demonstrating a lower reduction of DHA to VitC in
the db/db mouse. Figure 2B shows VitC/(VitC + DHA)
ratios in the kidneys of db/m and db/db mice at 8, 12,
and 16 weeks of age. For db/m mice, the VitC/(VitC +
DHA) ratios did not change significantly over time. For
db/db mice, the VitC/(VitC + DHA) ratios were 13%, 35%,
and 33% lower compared with the age-matched db/mmice
at 8, 12, and 16 weeks, respectively (P = 0.02, 0.03, and
0.02, respectively). A significant difference in the VitC/
(VitC + DHA) ratios was found among the db/db mice of
different ages (P = 0.01). Tukey-Kramer post hoc analysis
showed the VitC/(VitC + DHA) ratios were significantly
lower in the 12- and 16-week-old db/db mice compared
with those in the 8-week-old db/db mice (P , 0.05 for
both), but were not significantly different between the 12-
and 16-week-old db/db mice. PAS stains of the renal slices
demonstrated that the percent mesangial matrix area in-
creased over time in the db/db mice, at 13.9% for the
8-week-old db/db mice, 17.7% for the 12-week-old db/db
mice, and 20.4% for the 16-week-old db/dbmice (P = 0.02,
one-way ANOVA). The percent mesangial matrix area
Table 1—Body weights and blood glucose and 24-h urine albumin levels in db/db and db/m mice at various ages
Age (weeks) Body weight (g) Blood glucose (mg/dL) Urine albumin (mg/24 h)
db/m mice 8 26.7 6 1.4 146.5 6 10.2 13.5 6 5.2
12 27.0 6 2.4 135.7 6 16.5 15.3 6 3.1
16 29.9 6 0.8 145.3 6 30.1 17.9 6 5.4
db/db mice 8 35.9 6 1.6a 214.4 6 17.9a 185.4 6 35.1a
12 46.3 6 1.4a 378.2 6 25.0a 248.2 6 50.2a
12 (ramipril) 43.4 6 3.7a 370.4 6 36.2a 67.3 6 20.9a,b
16 48.3 6 4.7a 463.7 6 102.4a 320.1 6 65.5a
Data are mean 6 SE; n = 4 in each group. aP , 0.05 vs. age-matched db/m mice. bP , 0.05 vs. age-matched untreated db/db mice.
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was significantly higher in 12- and 16-week-old db/db
mice compared with 8-week-old db/db mice (P , 0.05
for both).
db/dbMice Have Decreased Renal GSH and Increased
Nox4 Expression Correlating to HP 13C DHA Finding
Since there is a redox coupling mechanism between
glutathione and VitC, we hypothesized that the observed
in vivo reduction of HP 13C DHA reflects changes in the
concentration of GSH. To test this hypothesis, we assayed
the kidneys of db/db and db/m mice for both GSH and
oxidized glutathione dimer (GSSG) concentrations using
an enzymatic recycling method (27). The results are sum-
marized in Fig. 3. For db/m mice, the GSH concentrations
did not change significantly among the three time points.
For db/db mice, the mean renal GSH concentrations were
18%, 26%, and 29% lower compared with age-matched
db/m mice at 8, 12, and 16 weeks of age, respectively
(P = 0.04, 0.003, and 0.02, respectively). The renal GSH/
GSSG ratios were 27%, 42%, and 38% lower in the db/db
mice compared with the db/m mice at 8, 12, and 16 weeks,
respectively (P = 0.04, 0.002, and 0.02, respectively). The
total glutathione (GSH + GSSG) concentrations in the db/db
mice were slightly lower than those in the age-matched db/m
mice, although they did not reach statistical significance
(P = 0.12, 0.06, and 0.08, respectively). We additionally
assayed the mRNA expression of Nox4, which has been
shown to be a major source of renal superoxide generation
in diabetes (8–13), as well as the expression of Nox1 and
Nox2. The renal Nox4 expression was significantly increased
in the db/db mice compared with db/mmice at all three time
points (P = 0.04, 0.03, and 0.03 for 8, 12, and 16 weeks,
respectively) (Fig. 3). The Nox2 expression was much lower
than that of Nox4, and was not significantly different be-
tween the db/db and db/m mice (Supplementary Fig. 1). The
Nox1 expression was very low (,1% of the control gene
HPRT) in the db/db and db/m mice (results not shown).
Ramipril Treatment Normalizes Renal HP 13C DHA
Reduction to VitC With Corresponding Restoration
of GSH Concentration and Nox4 mRNA Expression in
db/db Mice
Hyperglycemia has been shown to increases cellular
angiotensin II (Ang II) production (28), which in turn acti-
vates Nox4-mediated superoxide production and oxida-
tive stress (18). We treated a group of db/db mice with
an ACE inhibitor, ramipril, from 8 to 12 weeks of age and
Figure 2—Comparison of HP 13C DHA reduction in db/m and db/db
mice. A: Representative HP 13C MR spectra in a 12-week db/m and
db/db mouse. Kidney voxels demonstrate an approximately 50%
decrease in VitC production in db/db compared with db/m mouse.
B: Renal VitC/(VitC + DHA) ratios in db/db and db/m mice at 8, 12,
and 16 weeks of age. *Significant difference when compared with
age-matched db/m mice. #Significant difference when compared
with 8-week-old db/db mice.
Figure 3—Glutathione and Nox4 in db/db and db/m mice. A: GSH
and GSSG concentrations and GSH/GSSG ratios in the kidneys of
the db/m and db/db mice at 8, 12, and 16 weeks of age. The GSH
concentrations and GSH/GSSG ratios were significantly lower in
db/db mice compared with db/m mice at all three time points. B:
Renal Nox4 expression in db/m and db/db mice at 8, 12, and 16
weeks of age, demonstrating significantly higher Nox4 expression
in the db/db mice compared with the db/m mice. *P < 0.05.
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measured the in vivo HP 13C DHA reduction. We observed
that HP 13C DHA reduction to VitC in the kidneys of
treated 12-week-old db/db mice was restored to a level
similar to that found in age-matched db/m mice (Fig. 4A
and B). One-way ANOVA with post hoc analysis showed
that the VitC/(VitC + DHA) ratios were significantly lower
in the 12-week-old untreated db/db mice compared with
the 12-week-old db/m mice (P , 0.05) and the 12-week-
old treated db/db mice (P , 0.05). The VitC/(VitC + DHA)
ratios were not significantly different between the treated
db/db mice and the age-matched db/m mice. Similar
analyses also showed that there were no significant dif-
ferences between the treated db/db mice and the age-
matched db/m mice with regard to the renal GSH and
total glutathione concentrations, GSH/GSSG ratios, and
Nox4 mRNA expression level (Fig. 4C and D). Immunohis-
tochemical stains of 8-OHdG in renal slices demonstrate
increased staining, indicating increased oxidative DNA
damage, in the untreated db/db mice, which is diminished
with ramipril treatment (Fig. 4E). Similarly, 24-h urine
8-OHdG concentrations were increased in the untreated
db/db mice, and were normalized to the level in the db/m
mice after ramipril treatment (Fig. 4F). PAS stains of renal
slices demonstrate an increased mesangial matrix area in
the untreated db/db mice, which is diminished with treat-
ment (Fig. 4G).
DISCUSSION
Diabetic nephropathy is the major cause of end-stage
renal disease. Increased oxidative stress has been pro-
posed to be both a key initiator and a downstream effect
of a number of pathways involved in the pathogenesis of
diabetic nephropathy. In this study, we monitored, in real
time, the renal redox alteration associated with diabetes
and after treatment using HP 13C DHA MR. We showed
that the db/db mice have lower renal HP 13C DHA reduc-
tion to VitC compared with age-matched control mice.
After 4 weeks of treatment with an ACE inhibitor,
ramipril, the db/db mice show normalization of the HP
13C DHA reduction to VitC.
The observed alteration in the HP 13C DHA reduction
to VitC appears to reflect renal GSH concentration. GSH
is the most abundant intracellular thiol-based antioxi-
dant. It protects the cells from oxidative stress by pre-
venting the accumulation of ROS. GSSG, the oxidized
form of glutathione, is formed as a product of this de-
toxification. GSH is regenerated by the action of glutathi-
one reductase (EC 1.8.1.7), an NADPH-dependent enzyme,
thus completing the redox cycle. GSH is also a cofactor for
the enzyme DHA reductase (EC 1.8.5.1), which recycles
DHA back to reduced ascorbic acid (VitC), therefore link-
ing the redox couple between glutathione and VitC. GSH
alterations have been observed in diabetes and diabetic
nephropathy. For example, renal mesangial cells exposed
to chronic hyperglycemia have significantly decreased
GSH concentrations (29). Diabetic patients with micro-
albuminuria were noted to have lower GSH levels in red
blood cells than diabetic subjects without microalbumin-
uria (30). In agreement with these previous studies, we
found significantly lower concentrations of GSH and lower
GSH/GSSG ratios in the kidneys of db/db mice compared
with those of age-matched control mice at all three time
points. The observed changes in renal HP 13C DHA re-
duction to VitC appeared to reflect the changes in GSH
concentration. The mean VitC/(VitC + DHA) ratios in the
db/db mice were 13%, 35%, and 33% lower, respectively,
compared with the age-matched db/m mice at 8, 12, and
16 weeks of age. Correspondingly, the measured renal
GSH concentrations were 18%, 26%, and 29% lower, re-
spectively, in the db/db mice compared with age-matched
db/m mice at 8, 12, and 16 weeks of age.
We noted an early decrease in the renal VitC/(VitC +
DHA) ratios in the 8-week-old db/db mice. Phenotypically,
the 8-week-old db/db mice in our study demonstrated in-
creased albuminuria, but no significant glomerular histo-
logical changes compared with control mice. As the
duration of diabetes increased, the glomerular histological
changes, as assessed by mesangial matrix area, became
evident, although they remained relatively mild even in
the 16-week-old db/db mice. Taken together, these find-
ings support the notion that alterations in oxidative
stress/redox capacity are an early event and may play
a primary role in the development of diabetic nephropa-
thy (6,15,31). Noninvasive techniques such as HP 13C
DHA MR may facilitate future work to better understand
diabetic renal injury, such as the role that oxidative stress
plays in determining susceptibility to diabetic nephropa-
thy, as suggested by a previous study (32), and the tem-
poral relationship between oxidative stress and the
development of kidney injury.
Nox4 is an enzyme that has been reported to be
a major source of renal ROS in diabetes. Upregulation of
Nox4 together with increased superoxide generation has
been shown in response to high glucose concentration in
renal cells and in experimental models of diabetes (8–13).
In our study, the observed lower HP 13C DHA reduction
to VitC in the kidney of the db/db mice corresponded to
an increase in Nox4 expression. We postulate that this
may be due to Nox4-induced increase in superoxide gen-
eration with consumption of GSH (Fig. 5). It should be
noted that other sources or pathways are also involved in
the increased renal oxidative stress in diabetes. For exam-
ple, hyperglycemia leads to increased superoxide produc-
tion by the mitochondrial electron transport chain. This
process can in turn activate other superoxide production
pathways, such as via Nox4, that may amplify the original
damaging effect of hyperglycemia (33). Therefore, other
sources of oxidative stress may also contribute to the
observed alterations in renal GSH in the diabetic mice.
These additional sources likely contribute to the metabolic
phenotype reflected in lower HP 13C DHA reduction to
VitC in the diabetic kidneys.
It is well recognized that hyperglycemia increases
cellular Ang II production (28), which in turn activates
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Figure 4—HP 13C DHA reduction and correlative tissue studies in db/db mice after ramipril treatment. A: Representative HP 13C MR
spectra of a 12-week-old db/m mouse, an untreated db/db mouse, and a db/db mouse after 4 weeks of ramipril treatment. Kidney voxels
demonstrate normalization of VitC production in the db/db mouse after treatment to a level similar to that seen in the db/m mouse. Renal
VitC/(VitC + DHA) ratios (B); renal GSH, GSSG concentrations, and GSH/GSSG ratios (C); and renal Nox4 expressions (D ) demonstrate
similar findings. E: Representative immunostains of 8-OHdG in renal slices from 12-week-old db/m mice, untreated db/db mice, and
treated db/db mice demonstrate increased staining, indicating increased oxidative DNA damage, in the untreated db/db mice, which is
diminished with ramipril treatment. F: Twenty-four–hour urine 8-OHdG concentrations are significantly higher in the untreated db/db mice.
Ramipril-treated db/db mice show urine 8-OHdG concentrations similar to those in the db/m mice. G: Representative PAS stains of renal
slices from 12-week-old db/m mice (top left), untreated db/db mice (top middle), and treated db/db mice (top right), and the percent
mesangial matrix area demonstrate increased mesangial matrix area in the untreated db/dbmice (arrows), which is diminished with ramipril
treatment. *P < 0.05.
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Nox4-mediated superoxide production and oxidative
stress (18,34). ACE inhibitors, which decrease the produc-
tion of Ang II, and Ang II receptor blockers are commonly
used drugs for the treatment of diabetic nephropathy.
They are thought to protect the kidneys in part through
the reduction of oxidative stress (35,36) (Fig. 5). In this
study, we demonstrated that HP 13C DHA can monitor
the targeted effect of an ACE inhibitor (ramipril) on ox-
idative stress in vivo by observing the HP 13C DHA re-
duction to VitC. After 4 weeks of ramipril treatment, HP
13C DHA reduction to VitC in the kidneys of 12-week-old
db/db mice was restored to a level similar to that found in
age-matched db/m mice. The MR findings parallel the
normalization of renal GSH concentration and Nox4 ex-
pression. Because of the important role of oxidative stress
in the development and progression of diabetic nephrop-
athy as well as other forms of chronic kidney disease (37),
new pharmacological strategies that directly or indirectly
target oxidative stress are being explored (7,14,38). Non-
invasive techniques such as HP 13C DHA MR may provide
companion biomarkers that can provide better information
on drug targeting and enhance treatment monitoring.
It should be pointed out that, in general, cellular
DHA uptake may be facilitated by several factors such
as insulin, cyclic adenosine monophosphate, and colony-
stimulating factors (39–41) and suppressed by homocys-
teine (42). Such factors may potentially influence DHA
uptake into the renal cells of db/db mice with hyperinsu-
linemia and insulin resistance. Additionally, different cell
types within the renal glomeruli and tubules may differ-
entially reduce DHA to VitC due to different insulin sen-
sitivity or resistance. Therefore, future in vitro cell studies
using HP 13C DHA are warranted to elucidate the uptake
and reduction of DHA in different renal cells in a diabetic
milieu. It should also be noted that DHA reduction to
VitC can be affected by enzymes such as glutaredoxin
(Glrx) and glutathione S-transferase v (GSTO) that have
DHA reductase activity (43,44). The mRNA expressions of
Glrx-1 and GSTO-1, were noted to be higher in the db/db
mice compared with the db/m mice (Supplementary Fig.
2). Therefore, the observed lower renal HP 13C DHA re-
duction to VitC in the db/db mice compared with the db/m
mice cannot be explained by the alterations of expression
of these enzymes. Future studies are needed to investi-
gate the role that other enzymes play in the HP 13C DHA
reduction to VitC.
There are presently limited noninvasive in vivo meth-
ods for measuring oxidative stress in the kidneys. Urine
markers of oxidative stress, such as 8-OHdG (a marker
of DNA oxidative damage), have been used to study
Figure 5—Schematics illustrating the relationships among HP DHA, associated redox pairs, and Nox4. A: In response to persistent
hyperglycemia, renal Nox4 is upregulated and generates ROS (superoxide) by using NADPH as an electron donor. There is decreased
regeneration of GSH from GSSG and decreased reduction of HP DHA to VitC. B: Ramipril decreases Ang II production, which in turn
decreases Nox4 expression and ROS generation. Via the redox pairs of VitC and GSH, the treatment effect is observed as the normalization
of HP DHA reduction to VitC. The green box indicates GLUT1.
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diabetes-associated oxidative stress (45). Ex vivo measure-
ment of such markers, however, can be adversely affected
by variables, such as how the samples are collected and
stored (46), and may not accurately reflect oxidative
stress in real time at the tissue level. Electron spin reso-
nance (ESR) imaging has been applied to detect free rad-
icals in the kidneys in vivo (47). However, the sensitivity
of the ESR instruments for in vivo studies and the specificity
and stability of the probes are presently insufficient (48).
A recent study reported in vivo imaging of immunospin-
trapped radicals with MRI in a mouse diabetes model (49).
A drawback of this technique is that it required multiple
injections to trap radicals over the course of days (49).
Both the ESR imaging and immunospin-trapped radical
MRI assess oxidative stress by measuring radical levels.
HP 13C DHA MR provides a different approach of
determination of oxidative stress via real-time evaluation
of the redox capacity in vivo. In this preclinical study,
because of the small size of the mouse kidneys, the spatial
resolution of the HP 13C DHA MR does not currently
allow for separate evaluation of the renal cortex and me-
dulla. Several approaches will address this problem, in-
cluding better substrate polarization and coil design,
and more efficient sampling of k-space. These advances
will allow specific interrogation of the various renal com-
partments in preclinical models, as well as in potential
future clinical studies. An important consideration in the
clinical translation of HP 13C probes is that injection of
probes at doses in the micromolar-to-millimolar range is
necessary to achieve sufficient MR signals. While probes
such as 13C DHA have the advantage of being an endoge-
nous compound, the metabolic effects of the injected dose
and the safety in humans will need to be established.
Notably, the clinical translation of HP 13C MR technology
has been recently achieved with the successful completion of
the phase I clinical trial of HP 13C pyruvate in prostate
cancer patients (50), which opens doors for potential clinical
translation of other endogenous HP probes such as DHA.
In conclusion, our study has shown that HP 13C DHA
reduction to VitC correlates to the GSH component of the
redox couple, and likely reflects the impact of diabetes-
induced alterations in renal superoxide generation and
oxidative stress. HP 13C DHA can, in real time, noninva-
sively probe the redox changes associated with diabetic
renal injury and after successful treatment. Such an im-
aging approach may potentially enhance the prediction
and early detection of diabetic nephropathy and provide
companion biomarkers that can better inform on the re-
sponse to new therapies targeting oxidative stress in
patients. More broadly, such imaging strategies can be
extended to the noninvasive in vivo evaluation of other
complications from diabetes as well as other oxidative
stress-related diseases.
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